Vertex spends billions on CRISPR technology in search of diabetes cure
A new billion-dollar agreement with US gene editing firm Arbor Biotechnologies marks a continuation of biotech company Vertex's efforts to develop stem cell treatments, with a special focus on diabetes.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
US-based biotech company Vertex, known for its specialization within cystic fibrosis, has also been working towards a breakthrough for treating type 1 diabetes over the past few years. That innovation is now a step closer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Experts: The world needs more than just mRNA vaccines
For subscribers
